BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces the launch of Oravig® (known as Loramyc® in Europe) in the United States by its commercial partner, Vestiq Pharmaceuticals.
Just three months after the signature of the license agreement between the two Companies, commercial teams have begun the active promotion of Oravig® to US prescribers and wholesalers.
Based in North Carolina, Vestiq is a company dedicated to the commercialization of innovative, effective and safe therapeutic products designed to meet needs of patients requiring specific care. Following the recent acquisition of Praelia Pharmaceuticals by Vestiq Pharmaceuticals, Oravig® commercial operations will be driven directly by Praelia, the operational subsidiary. Vestiq has developed a specialized portfolio of therapeutic innovations dedicated to cancer supportive care, among which Oravig®, indicated for the treatment of oropharyngeal candidiasis, holds a strategic position.
“Thanks to its know-how, Vestiq’s team has created and implemented an ambitious promotion plan to commercialize Oravig® in early 2013”, said Judith Greciet, CEO of BioAlliance Pharma. “The professionalism and the efficiency of our partner’s commercial teams are solid assets to ensure the success of Oravig® in the US. For BioAlliance, the commercialization of Oravig® is a key factor that should contribute to its future sales growth”.
Martin Baum, Chairman and CEO of Vestiq Pharmaceuticals, stated: “We are very excited to be launching Oravig® into the US market as part of our dedicated supportive care portfolio. Oravig® and its associated technology provide ease of use and treatment compliance for the patient who has difficulty in swallowing. The launching of Oravig® additionally cements our focus in becoming the leader in supportive care products and technologies”.